|
|
|
| Esperoct® is used to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Please see full indication and limitation below. |
|
|
|
| Did you know Esperoct® has a flexibility factor?a |
|
|
|
| Did you know Esperoct® has a flexibility factor?a |
| See how Esperoct® takes the heat |
| Esperoct® has a flexibility factor that can fit into your active lifestyle. Take it with you on the go, even on hot days. |
|
 |
Esperoct® is the only extended half-life product that can go with you up to 104 °Fa |
|
|
 |
After reconstitution, Esperoct® can be used up to 4 hours at up to 86 °Fb |
|
|
 |
After reconstitution, you can store Esperoct® in the refrigerator for up to 24 hoursb,c |
|
|
 |
Esperoct® is ready in 3 simple steps—infuse in 2 minutesd |
|
|
|
 |
Esperoct® offers portable and flexible storage across all age groups with hemophilia A |
|
|
|
|
| bSee Prescribing Information for complete product storage information. Store reconstituted product in vial. |
| cAfter reconstitution, Esperoct® can be stored in the refrigerator between 36 °F to 46 °F for up to 24 hours. |
| dFor full instructions, please see the Instructions for Use provided with the Prescribing Information. |
|
| Selected Important Safety Information |
| Who should not use Esperoct®? |
| |
• |
You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins |
|
| What is the most important information I need to know about Esperoct®? |
| |
• |
Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
|
|
| |
• |
Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
Discover bleed protection
with Esperoct® |
|
|
|
|
 |
| Get support in your community |
| Connect with a Rare Blood Community Liaison (RBCL) to get personalized support, find local events, and learn more about Esperoct®. |
|
|
|
|
|
|
| What is Esperoct®? |
| Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery |
| |
• |
Esperoct® is not used to treat von Willebrand Disease |
|
| Important Safety Information (cont’d) |
| What should I tell my healthcare provider before using Esperoct®? |
| |
• |
Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII |
| |
• |
Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct® |
|
| What are the possible side effects of Esperoct®? |
| |
• |
Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion |
|
| Please click here for Prescribing Information. |
| Esperoct® is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. |
| Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
|
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2024 Novo Nordisk All rights reserved. US24ESP00081 November 2024 |
 |
|
|
|
